On December 31, 2021, Charles H. Randall, chief strategy officer of SAB Biotherapeutics, Inc. resigned. The company and Mr. Randall are finalizing the terms of a release and severance under his employment agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.83 USD | -3.74% | +9.69% | -58.84% |
Jun. 20 | SAB Biotherapeutics, Inc. has Changed its Name to SAB BIO | CI |
Jun. 07 | Brookline Capital Initiates SAB Biotherapeutics With Buy Rating, $8 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.84% | 27.13M | |
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- SAB Biotherapeutics, Inc. Announces Resignation of Charles H. Randall as Chief Strategy Officer